4.4 Review

Aurora kinase inhibitors as anti-cancer therapy

期刊

ANTI-CANCER DRUGS
卷 21, 期 4, 页码 339-350

出版社

LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/CAD.0b013e3283350dd1

关键词

AT9283; aurora kinase inhibitors; AZD1152; ENMD-2076; MLN8237; PF03814735; PHA739358; SNS-314; VX680/MK0457; VX689/MK5108

向作者/读者索取更多资源

Aurora kinases are serine and threonine kinases that function as key regulators of the mitosis process. There are three distint human aurora kinases known as Aurora A, Aurora B, and Aurora C. Aurora A and Aurora B are overexpressed in a number of human cancers including non-small cell lung cancer, glioblastomas, and upper gastrointestinal adenocarcinomas. Given their association with tumorigenesis, both Aurora A and Aurora B have been targeted for cancer therapy. Currently, a number of selective and nonselective aurora kinase inhibitors are being tested in preclinical and clinical settings as anti-tumor agents. We review the biology of human aurora kinases, followed by an overview of inhibitors undergoing current clinical investigations. Anti-Cancer Drugs 21: 339-350 (C) 2010 Wolters Kluwer Health vertical bar Lippincott Williams & Wilkins.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.4
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据